Brussels, Belgium and Noáin, Spain, 17 August 2021 – Precirix NV, a clinical-stage biotechnology company developing novel radiopharmaceuticals in oncology, and 3P Biopharmaceuticals S.L.U. (3P), a leading CDMO based in Spain specializing in process development and GMP manufacturing of biological products, have signed an agreement for the clinical manufacturing of a camelid single domain antibody fragment (sdAb), the backbone of Precirix’ next product candidate to enter the clinic.
As Precirix’ lead compound, CAM-H2, is being evaluated in a Phase I/II clinical trial, the company is advancing its second product candidate towards the clinic. Large-scale manufacturing of the sdAb backbone is an important first step in this process. 3P Biopharmaceuticals will complete the technology transfer, process upscaling and manufacturing of the sdAb.
“This collaboration marks an important step in advancing our second pipeline program towards the clinic. We are confident 3P is the right partner for the manufacturing of our highly selective single domain antibody”, said Ruth Devenyns, Chief Executive Officer of Precirix.
Dámaso Molero, Chief Executive Officer of 3P Biopharmaceuticals commented: "The alliance with Precirix is an exciting new venture for 3P, where, once again, innovation and technology come together making it possible to develop novel drugs against cancer. We look forward to being part of the Precirix journey.”
Your browser is not supported. Update your browser for more security, speed and to make the most of this site.